Connect Biopharma Holdings Stock Price Patterns
| CNTB Stock | USD 2.30 0.03 1.29% |
Momentum 62
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.27) | EPS Estimate Current Year (1.03) | EPS Estimate Next Year (0.81) | Wall Street Target Price 7.9 | EPS Estimate Current Quarter (0.24) |
Using Connect Biopharma hype-based prediction, you can estimate the value of Connect Biopharma Holdings from the perspective of Connect Biopharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Connect Biopharma using Connect Biopharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Connect using crowd psychology based on the activity and movement of Connect Biopharma's stock price.
Connect Biopharma Implied Volatility | 1.44 |
Connect Biopharma's implied volatility exposes the market's sentiment of Connect Biopharma Holdings stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Connect Biopharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Connect Biopharma stock will not fluctuate a lot when Connect Biopharma's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Connect Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Connect because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Connect Biopharma after-hype prediction price | USD 2.42 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Connect Biopharma Basic Forecasting Models to cross-verify your projections. Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Connect Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Connect Biopharma After-Hype Price Density Analysis
As far as predicting the price of Connect Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Connect Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Connect Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Connect Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Connect Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Connect Biopharma's historical news coverage. Connect Biopharma's after-hype downside and upside margins for the prediction period are 0.12 and 9.17, respectively. We have considered Connect Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Connect Biopharma is very risky at this time. Analysis and calculation of next after-hype price of Connect Biopharma is based on 3 months time horizon.
Connect Biopharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Connect Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Connect Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Connect Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.89 | 6.75 | 0.09 | 0.22 | 8 Events / Month | 6 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
2.30 | 2.42 | 3.86 |
|
Connect Biopharma Hype Timeline
Connect Biopharma is currently traded for 2.30. The entity has historical hype elasticity of 0.09, and average elasticity to hype of competition of -0.22. Connect is anticipated to increase in value after the next headline, with the price projected to jump to 2.42 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 3.86%, whereas the daily expected return is currently at 0.89%. The volatility of related hype on Connect Biopharma is about 2789.26%, with the expected price after the next announcement by competition of 2.08. Connect Biopharma Holdings currently holds 178 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Given the investment horizon of 90 days the next anticipated press release will be in about 8 days. Check out Connect Biopharma Basic Forecasting Models to cross-verify your projections.Connect Biopharma Related Hype Analysis
Having access to credible news sources related to Connect Biopharma's direct competition is more important than ever and may enhance your ability to predict Connect Biopharma's future price movements. Getting to know how Connect Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Connect Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| IFRX | InflaRx NV | (0.06) | 9 per month | 0.00 | (0.08) | 7.92 | (9.28) | 43.11 | |
| IMA | ImageneBio | (0.05) | 5 per month | 0.00 | (0.09) | 6.76 | (5.18) | 18.29 | |
| KLRS | Kalaris Therapeutics | (0.45) | 5 per month | 4.24 | 0.17 | 15.58 | (8.21) | 32.70 | |
| STTK | Shattuck Labs | (0.06) | 7 per month | 2.84 | 0.23 | 6.42 | (4.82) | 27.07 | |
| ARTV | Artiva Biotherapeutics Common | (1.62) | 7 per month | 7.41 | 0.05 | 8.00 | (11.11) | 118.69 | |
| STRO | Sutro Biopharma | 0.07 | 9 per month | 5.18 | 0.08 | 11.76 | (7.78) | 27.28 | |
| MGX | Metagenomi Common Stock | 0.02 | 8 per month | 0.00 | (0.18) | 6.02 | (6.21) | 19.55 | |
| CNTX | Context Therapeutics | (0.11) | 8 per month | 3.46 | 0.24 | 9.59 | (6.09) | 24.11 | |
| QNCX | Quince Therapeutics | (0.15) | 11 per month | 0.00 | (0.06) | 11.88 | (13.15) | 120.72 | |
| OVID | Ovid Therapeutics | (0.01) | 7 per month | 4.82 | 0.04 | 9.20 | (9.09) | 36.13 |
Connect Biopharma Additional Predictive Modules
Most predictive techniques to examine Connect price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Connect using various technical indicators. When you analyze Connect charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Connect Biopharma Predictive Indicators
The successful prediction of Connect Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Connect Biopharma Holdings, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Connect Biopharma based on analysis of Connect Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Connect Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Connect Biopharma's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Net Debt To EBITDA | 1.8 | 3.58 | 3.22 | 3.38 | Intangibles To Total Assets | 4.92E-4 | 5.23E-4 | 4.71E-4 | 4.47E-4 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Complementary Tools for Connect Stock analysis
When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |